Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aditya Raghunath

Up 163% YTD, Is It Too Late to Buy MindMed Stock?

Valued at $645 million by market cap, Mind Medicine (MNMD), also known as MindMed, is a clinical-stage biopharma company developing novel product candidates to treat brain health disorders. Shares of the company went public in March 2020, and touched a record high 12 months later. Today, MindMed stock trades 88% below its all-time highs - but MNMD has more than doubled its market value in 2024, up 163.9% on a year-to-date basis.

Let’s see if you should hold Mind Medicine stock in your equity portfolio right now. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.